887 Great Northern Way, Suite 138 Vancouver, British Columbia V5T 4T5 Canada office 604.734.1450 • fax 604.676.2235 [email protected] • www.qubiologics.com

TITLE

Chief Financial Officer

REPORTING RELATIONSHIP

The Chief Financial Officer will report to Hal Gunn, M.D., CEO and will be an essential member of the Executive Team and an Officer of the Company.

The Chief Financial Officer will be responsible for all finance functions, including financial and expense projections (through to drug approval, revenue generation and beyond for the SSI platform), financial and funding strategy, fundraising (angel investors, VCs, investments banks), investor relations, pharma partnerships, deal analysis, financial reporting, compliance, controls, budgeting, pricing, tax, real estate, treasury, as well as IT and facilities functions. The total number of direct reports will eventually include Controller, Director of Investor Relations, Director of IT and Director of Finance. Additional reporting departments may be added in the future. However, the successful candidate must feel comfortable ‘wearing multiple hats’ and managing ‘hands on’ each of these areas by himself/herself, since the positions listed above will not be hired until the successful completion of the company’s current Crohn’s disease clinical trial. In other words, the successful candidate must be prepared for growth but understand and embrace the practical realities of a ‘hands on’ entrepreneurial emerging biotech environment.

COMPANY PROFILE

Qu Biologics is developing a platform of new immunotherapeutic treatments for cancer and other chronic inflammatory diseases. The company’s Site Specific Immunomodulators (SSIs) are designed to activate the innate immune system to restore normal immune function and reverse the chronic inflammation underlying many chronic diseases, including cancer and Crohn’s disease.

More than 270 patients with advanced cancer, inflammatory bowel disease and arthritis have been treated with Qu Biologics’ SSIs through compassionate use programs. The preliminary clinical findings suggest excellent safety profile and promising outcomes, which support further research in controlled clinical trials.

The company is currently recruiting for a Phase 1/2b randomized placebo- controlled clinical trial in Crohn’s disease and a Phase 2a clinical trial in recurrent lung cancer. A third trial, a Phase 2a trial in ulcerative colitis is scheduled to begin in Q2 2015. A fourth trial, a Phase 2b randomized clinical trial in late stage lung cancer, is slated to begin in Q1 2016.

Qu Biologics’ goal is to develop SSIs to improve the survival and quality of life of millions of people fighting cancer and the quality of life of people living with debilitating immune-related diseases such as Crohn’s disease, ulcerative colitis and rheumatoid arthritis.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumors, Robert Cory, PhD and MBA, Vice President of Business Development and Gillian Vandermeirsch, PhD, Vice President of Operations.

For additional information please visit www.qubiologics.com

IS QU FOR YOU?

You value integrity, honesty and humility. You love new ideas and innovation and working with an intelligent, creative, fun and inspired team in an organization of excellence. You know that opportunity lies in doing things differently and that the way that things are usually done is not always the best way of doing things. You recognize that character is more important than skills. You love working with other people who value respectful communication, inspired teamwork and working together to achieve shared goals. You want to make a difference in the world and work with people who feel the same. You love thinking ‘outside’ the box and working with others who share a creative, fun and practical approach to innovation.

LOCATION

Qu Biologics is located in Vancouver, British Columbia, Canada.

COMPENSATION

The successful candidate will receive a competitive compensation package to include salary, equity participation and a company benefits package.

SCOPE OF ACCOUNTABILITY

Lead Qu’s financial and funding strategy, including expense projections (through to drug approval, revenue generation and beyond) and the exploration and planning of the financial and funding options available to the company (which include private equity funding, non-dilutive funding, IPO and pharma partnerships). Present these fully defined options to the CEO, executive team and Board of Directors. Lead the planning, implementation and execution of the selected option(s).

Must be able to play a key role on the senior management team and serve as a business confidant and partner to the CEO and contribute extensively at the Board level.

Lead the development of the company’s business plan, including working with the CEO and CMO to prioritize lead SSI drug candidates and SSI development options by leading the forecasting of funding requirements for the clinical plans for each of the lead SSI drug candidates and indications through to the selected strategic outcome (i.e., drug approval and/or pharma partnership).

Actively participate and contribute in strategic planning and establishment of financial objectives with the CEO, and securing adequate financing to realize objectives. Assure that stable, well-developed and secure financial systems are in place.

Presentations to potential investors and at investor conferences, including presentations to angel investors, investment banks, VCs and potential pharma partners. Must be able to clearly articulate the scientific story to the investment community including frequent presentations at key meetings.

Responsibilities will include corporate positioning, deal analysis, reporting, public relations, press releases and, potentially, SEC regulatory compliance.

Manage all accounting, finance and other related functions within the Company. Coordinate budget planning and provide proper tracking and reporting to management team on results.

Manage all IT and facilities functions.

Assure necessary compliance on all tax, reporting, regulatory and financial obligations. Coordinate and supervise the management of all transactions related to investments, accounts payable and purchasing.

Must have a keen interest and capability of bringing the kind of innovative culture that exists in the technology industry to the conservative biotech/pharma industry.

QUALIFICATIONS

A proven business executive who is strategic, practical and hands-on and goes beyond the financial role and serves as a key executive in all aspects of the business. An innovative entrepreneur who loves working with other bright creative people, and has a strong interest in, and strong ability to, create and support an organization of excellence. Must be comfortable in an innovative, creative, fast paced environment, with experience playing a key role in corporate operations. Able to quickly and clearly translate operational issues into financial consequences and financial decisions into operational consequences.

An IPO is one financing option for Qu. Experience having raised and closed equity investments and navigating the company through a Nasdaq Initial Public Offering is desirable. A solid network of contacts with leading investment banks and equity research analysts is preferred.

Pharma partnership is another financing option for Qu. Experience in negotiating and closing major financial transactions, including pharma partnerships, is desirable.

An undergraduate degree in Accounting or Finance plus a CPA or MBA is preferred. Minimum of 10+ years in leadership and all accounting, finance and treasury functions. Proven ability to build, manage and lead an effective and efficient finance organization and high performance team. Practical ‘hands on’ operations experience is highly desirable.

Deep understanding of the culture and environment of an organization of excellence and an early-stage and rapidly growing organization is essential.

Experience as a CFO or senior-level financial executive in a publicly traded company is desirable, with recent (preferably <5 years) exposure to Wall Street, the analyst community and the investment community. Appropriate SEC compliance and reporting experience is preferred since an IPO is one financing option for the company.

A solid base of experience in a private and emerging biotechnology company is desirable, including financial leadership of a biotechnology or pharma company that has developed drugs through to commercialization, including Phase 1, 2 and 3 clinical trials.

Astute, decisive, hands-on finance executive proven to excel in a dynamic environment. Must bring value-added qualifications to a rapid growth company, including overseeing business development and funding opportunities.

Able to identify, recruit and retain high potential talent to the organization, with experience from both corporate and entrepreneurial environments, to nurture and support an organization of excellence.

Team player with executive presence and demeanor coupled with superb written and oral communications and presentation skills.

DESIRABLE TRAITS AND SKILLS

Qu Biologics has assembled a highly functioning and close knit executive team that is committed to building a culture of high integrity, leadership excellence and innovation. The final candidate will be chosen with these three critical characteristics being a key part in their evaluation.

Polished, hands-on, decisive team player/builder who will take responsibility for the development of a well-integrated financial organization.

Ability to maintain healthy and positive relationships with institutional investors, investment banks and equity analysts is essential, including the ability to build a market for the company stock post-IPO.

Capable of working well with all functional areas in the development of a team. This should include the ability to share in the success and failure of others. Ability to think strategically and execute effectively.

Comfortable being a change agent inside the company beyond the financial group in order to help catalyze the entire organization.

A solid base of skills and accomplishments in roles assisting with the development and negotiation of licensing agreements, partnering relationships, development of alliances and other related partnering, finance and investor activities.

The successful candidate should possess the following skills and attributes:

 Intelligent  Hands-on/detail oriented  Strategic planning skills  Leadership  Analytical  Resilient  Transparent communicator  Innovative and creative

DESIRED START DATE

This is a newly created position, and will be filled when the optimal candidate is identified and able to start.

HOW TO APPLY

If this opportunity matches your leadership character, experience and skill set, and you would like to help lead an exciting and dynamic team, researching proprietary immunotherapies for cancer and autoimmune disease, the position is open and we are looking for the right candidate to fill this new position. Please email a cover letter and your resume in Microsoft Word (.doc/.docx) or PDF format, to: [email protected].

We thank all applicants for their interest in a position at Qu Biologics. We regret that only those selected for an interview will be contacted. Please note that we will not be fielding inquires by phone.